By
Wendy Carr, PhD; Ekaterina Kurbatova, MD, PhD, MPH; Bria Marlow, MPH, CHES; Meredith Moore, MPH
Published: July 8, 2022, 9:47 p.m.·
Tags:
Drug-sensitive TB,
Treatment,
Guidelines
On February 24, 2022, the Centers for Disease Control and Prevention (CDC) published new interim guidance in Morbidity and Mortality Weekly Report on a 4-month treatment regimen as an option for US patients with drug-susceptible pulmonary tuberculosis (TB).[1] The 4-month treatment regimen consists of high-dose daily rifapentine with moxifloxacin, isoniazid, and pyrazinamide. Shorter regimens help patients complete treatment faster.
Read More →
